Evidence of superiority of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors or angiotensin ii receptor blockers in the heart failure with reduced ejection fraction patient's journey

Evidence of superiority of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors or angiotensin ii receptor blockers in the heart failure with reduced ejection fraction patient's journey

Sacubitril/valsartan (S/V) is a new drug which has been recently recommended by the international guidelines for the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF). Compared to angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor b...

Full description

Bibliographic Details
Main Authors: Mauro Gori, Emilia D'Elia, Michele Senni
Format: Article
Language:English
Published: Wolters Kluwer Health/LWW 2021-01-01
Series:Cardiology Plus
Subjects:
heart failure; real-world evidence; reverse remodeling; sacubitril-valsartan
Online Access:http://www.cardiologyplus.org/article.asp?issn=2470-7511;year=2021;volume=6;issue=1;spage=23;epage=29;aulast=Gori

Internet

http://www.cardiologyplus.org/article.asp?issn=2470-7511;year=2021;volume=6;issue=1;spage=23;epage=29;aulast=Gori

Similar Items